{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-015081","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.269346+00:00","generated_at":"2026-05-17T05:33:40.511881+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipocine delays LPCN 2401 POC study, seeks FDA clarity on endpoints","bullets":["Received IND clearance for LPCN 2401 as adjunct to GLP-1 therapy.","Seeking regulatory clarity on POC study endpoints, including functional loss.","POC study on hold pending FDA feedback; corporate presentation updated.","No timeline provided for resolution; development path uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-015081","json":"https://secwatch.observer/filing/0001493152-25-015081.json","markdown":"https://secwatch.observer/filing/0001493152-25-015081.md","text":"https://secwatch.observer/filing/0001493152-25-015081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225015081/0001493152-25-015081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225015081/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:33:40.511881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}